Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.
On July 28, 2025, MAIA Biotechnology announced that the FDA granted Fast Track designation for ateganosine, a treatment for non-small cell lung cancer (NSCLC). Ateganosine, currently in a pivotal Phase 2 clinical trial, has shown promising results with a median overall survival of 17.8 months, significantly longer than standard treatments. This designation could accelerate its approval process, potentially positioning ateganosine as a first-to-market treatment in the $34 billion NSCLC market, addressing a significant unmet medical need.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company’s lead program involves ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 399,570
Technical Sentiment Signal: Sell
Current Market Cap: $51.52M
Learn more about MAIA stock on TipRanks’ Stock Analysis page.